Subscribe to access the summary in 20 seconds.
The agreement established by the United States and the European Union led to the establishment of customs duties up to 15% on pharmaceutical products. The 39% imposed on Switzerland by Donald Trump do not a priori concern the sector, which had been exempt during the announcements of April 2. However, the time is far from being relieved, in particular due to the threat of customs duties specific to the pharmaceutical industry which continues to hover.
“The new measures lastingly compromise economic relations between the two countries, with negative consequences for both parties,” reacted science and one of the ridges in the sector, in a press release. Pharmaceutical products are part of complex and interconnected supply chains worldwide. New customs duties would weigh heavily on these structures, which would lead to growing uncertainty for businesses and serious risks for the supply of vital drugs, in particular in the United States. ”
